首站-论文投稿智能助手
典型文献
A novel anticancer property of Lycium barbarum polysaccharide in triggering ferroptosis of breast cancer cells
文献摘要:
Breast cancer is one of the most malignant tumors and is associated with high mortality rates among women. Lycium barbarum polysaccharide (LBP) is an extract from the fruits of the traditional Chinese herb, L. barbarum . LBP is a promising anticancer drug, due to its high activity and low toxicity. Although it has anticancer properties, its mechanisms of action have not been fully established. Ferroptosis, which is a novel anticancer strategy, is a cell death mechanism that relies on iron-dependent lipid reactive oxygen species (ROS) accumulation. In this study, human breast cancer cells (Michigan Cancer Foundation-7 (MCF-7) and MD Anderson-Metastatic Breast-231 (MDA-MB-231)) were treated with LBP. LBP inhibited their viability and proliferation in association with high levels of ferroptosis. Therefore, we aimed to ascertain whether LBP reduced cell viability through ferroptosis. We found that the structure and function of mitochondria, lipid peroxidation, and expression of solute carrier family 7 member 11 (SLC7A11, also known as xCT, the light-chain subunit of cystine/glutamate antiporter system Xc?) and glutathione peroxidase 4 (GPX4) were altered by LBP. Moreover, the ferroptosis inhibitor, Ferrostatin-1 (Fer-1), rescued LBP-induced ferroptosis-associated events including reduced cell viability and glutathione (GSH) production, accumulation of intracellular free divalent iron ions and malondialdehyde (MDA), and down-regulation of the expression of xCT and GPX4. Erastin (xCT inhibitor) and RSL3 (GPX4 inhibitor) inhibited the expression of xCT and GPX4, respectively, which was lower after the co-treatment of LBP with Erastin and RSL3. These results suggest that LBP effectively prevents breast cancer cell proliferation and promotes ferroptosis via the xCT/GPX4 pathway. Therefore, LBP exhibits novel anticancer properties by triggering ferroptosis, and may be a potential therapeutic option for breast cancer.
文献关键词:
作者姓名:
Xing DU;Jingjing ZHANG;Ling LIU;Bo XU;Hang HAN;Wenjie DAI;Xiuying PEI;Xufeng FU;Shaozhang HOU
作者机构:
Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education,School of Basic Medical Sciences,Ningxia Medical University,Yinchuan 750004,China;Department of Clinical Pathology,School of Basic Medical Sciences,Ningxia Medical University,Yinchuan 750004,China
引用格式:
[1]Xing DU;Jingjing ZHANG;Ling LIU;Bo XU;Hang HAN;Wenjie DAI;Xiuying PEI;Xufeng FU;Shaozhang HOU-.A novel anticancer property of Lycium barbarum polysaccharide in triggering ferroptosis of breast cancer cells)[J].浙江大学学报(英文版)(B辑:生物医学和生物技术),2022(04):286-299
A类:
B类:
novel,anticancer,property,Lycium,barbarum,polysaccharide,triggering,ferroptosis,breast,cells,Breast,most,malignant,tumors,associated,high,mortality,rates,among,women,LBP,extract,from,fruits,traditional,Chinese,herb,promising,drug,due,activity,toxicity,Although,has,properties,mechanisms,action,have,not,been,fully,established,Ferroptosis,which,strategy,death,that,relies,iron,dependent,lipid,reactive,oxygen,species,ROS,accumulation,In,this,study,human,Michigan,Cancer,Foundation,MCF,Anderson,Metastatic,MB,were,treated,inhibited,their,viability,proliferation,association,levels,Therefore,aimed,ascertain,whether,reduced,through,We,found,structure,function,mitochondria,peroxidation,expression,solute,carrier,family,member,SLC7A11,also,known,xCT,light,chain,subunit,cystine,glutamate,antiporter,system,Xc,glutathione,peroxidase,GPX4,altered,by,Moreover,inhibitor,Ferrostatin,rescued,induced,including,GSH,production,intracellular,free,divalent,ions,malondialdehyde,down,regulation,Erastin,RSL3,respectively,was,lower,after,co,treatment,These,results,suggest,effectively,prevents,promotes,pathway,exhibits,may,potential,therapeutic,option
AB值:
0.558478
相似文献
The structure of erastin-bound xCT-4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis
Renhong Yan;Enjun Xie;Yaning Li;Jin Li;Yuanyuan Zhang;Ximin Chi;Xueping Hu;Lei Xu;Tingjun Hou;Brent R.Stockwell;Junxia Mini;Qiang Zhou;Fudi Wang-Westlake Laboratory of Life Sciences and Biomedicine,Key Laboratory of Structural Biology of Zhejiang Province,Institute of Biology,Westlake Institute for Advanced Study,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Department of Biochemistry,School of Medicine,Southern University of Science and Technology,Shenzhen,Guangdong,China;The First Affiliated Hospital,The Fourth Affiliated Hospital,School of Public Health,Institute of Translational Medicine,Cancer Center,State Key Laboratory of Experimental Hematology,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;The First Affiliated Hospital,The Second Affiliated Hospital,Basic Medical Sciences,School of Public Health,Hengyang Medical School,University of South China,Hengyang,Hunan,China;Beijing Advanced Innovation Center for Structural Biology,Tsinghua-Peking Joint Center for Life Sciences,School of Life Sciences,Tsinghua University,Beijing,China;Hangzhou Institute of Innovative Medicine,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou,Zhejiang,China;Institute of Bioinformatics and Medical Engineering,Jiangsu University of Technology,Changzhou,Jiangsu,China;Department of Biological Sciences and Department of Chemistry,Columbia University,New York,NY,USA
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models
Ming Ji;Dongjie Wang;Songwen Lin;Chunyang Wang;Ling Li;Zhihui Zhang;Jing Jin;Deyu Wu;Yi Dong;Heng Xu;Duo Lu;Xiaoguang Chen-State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease
Jie Tong;Dongjie Li;Hongbo Meng;Diyang Sun;Xiuting Lan;Min Ni;Jiawei Ma;Feiyan Zeng;Sijia Sun;Jiangtao Fu;Guoqiang Li;Qingxin Ji;Guoyan Zhang;Qirui Shen;Yuanyuan Wang;Jiahui Zhu;Yi Zhao;Xujie Wang;Yi Liu;Shenxi Ouyang;Chunquan Sheng;Fuming Shen;Pei Wang-Department of Pharmacy,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Nuclear Medicine,Tongji University School of Medicine,Shanghai 200072,China;Department of General Surgery,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Department of Pharmacology,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China;Department of Pharmacy,Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China;Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University,Shanghai 200241,China;Chemical Biology Research Center School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325000,China;Department of Medicinal Chemistry,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China
Mitochondrial aldehyde dehydrogenase(ALDH2)rescues cardiac contractile dysfunction in an APP/PS1 murine model of Alzheimer's disease via inhibition of ACSL4-dependent ferroptosis
Zhi-yun Zhu;Yan-dong Liu;Yan Gong;Wei Jin;Elena Topchiy;Subat Turdi;Yue-feng Gao;Bruce Culver;Shu-yi Wang;Wei Ge;Wen-liang Zha;Jun Ren;Zhao-hui Pei;Xing Qin-Jiangxi Provincial People's Hospital Affiliated to Nanchang University,Nanchang 330006,China;The Second Department of Cardiology,The Third Hospital of Nanchang,Nanchang 330009,China;University of Wyoming College of Health Sciences,Laramie,WY,USA;State Key Laboratory of Animal Nutrition,College of Animal Science and Technology,China Agricultural University,Beijing 100083,China;Department of General Practice,Xijing Hospital,the Air Force Military Medical University,Xi'an 710032,China;Department of Surgery,Clinic Medical College,Hubei University of Science and Technology,Xianning 437100,China;National Demonstration Center for Experimental General Medicine Education,Hubei University of Science and Technology,Xianning 437100,China;Department of Cardiology and Shanghai Institute of Cardiovascular Diseases,Zhongshan Hospital Fudan University,Shanghai 200032,China;Department of Cardiology,Xijing Hospital,the Air Force Military Medical University,Xi'an 710032,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。